NCT05132244Recruiting
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
Pancreatic Cancer Glucose Assessment and Regulation Study
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer. Sugar levels will be monitored with blood draws prior to each cycle of anti-cancer treatment until treatment ends or the participant's cancer worsens. Participants may receive any first-line systemic therapy for pancreatic cancer, including treatments given as part of another clinical trial. If treatment is needed to manage blood sugar levels, the treatment will be given according to the standard of care. All participants will be enrolled into the same group.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 10 Nov 2021
- Start date
- 16 Apr 2024
- Primary completion date
- Oct 2028
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Pancreatic cancer
- NCT number
- NCT05132244
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 16 Apr 2024 to the primary completion date, Oct 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received prior systemic therapy (chemotherapy or any other anti-cancer agent) for treatment of metastatic PDAC. Participants who received adjuvant chemotherapy after surgical resection of early stage disease are eligible.
- Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent).
Other illness
- Known diagnosis of type II diabetes and already followed by Endocrinologist.
Lab values
- Known diagnosis of type I diabetes where strict glucose control and close Endocrinology follow-up is already indicated.
Other
- Absence of distant or lymph node metastases. Participants with borderline resectable or locally advanced PDAC are not eligible.
- Presence of brain metastases.
- Participants with a positive pregnancy test.
- Participants who are not safe to include in the study as judged by the study doctor for any medical or non-medical reason.
- Unable to comply with study assessments and follow-up.
Who the study is looking for
- Histological/cytological diagnosis of pancreatic ductal adenocarcinoma (PDAC).
- Planned to undergo first-line systemic therapy.
- Age greater than or equal to 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Adequate bone marrow and organ function as defined by the following laboratory values:
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L.
- Platelet count greater than or equal to 75 x 10\^9/L.
- Hemoglobin greater than or equal to 9.0 g/dL.
- Estimated glomerular filtration rate (GFR) by Cockroft-Gault equation OR 24 hour urine collection greater than or equal to 40 ml/min.
- Creatinine clearance greater than or equal to 40 mL/min using Cockcroft-Gault formula.
- Potassium within normal limits, or corrected with supplements.
- International normalized ratio (INR) less than or equal to 1.5.
- Total serum bilirubin less than or equal to 2 x upper limit of normal (ULN) (any elevated bilirubin should be asymptomatic at enrollment) except for participants with documented Gilbert's syndrome who may only be included if the total bilirubin less than or equal to 3 x ULN or direct bilirubin less than or equal to 1.5 x ULN).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN (or less than or equal to 5 x ULN if liver metastases are present).
- Able to understand and voluntarily sign the informed consent form.
- Able to comply with the study visit schedule and other protocol requirements.
- Able to swallow oral medications.
- Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 at baseline.
- Life expectancy of more than 90 days as judged by the study doctor.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| British Columbia Cancer Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.